Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 40,600 shares, a growth of 82.9% from the August 31st total of 22,200 shares. Based on an average trading volume of 684,200 shares, the days-to-cover ratio is currently 0.1 days. Currently, 3.3% of the shares of the company are short sold. Currently, 3.3% of the shares of the company are short sold. Based on an average trading volume of 684,200 shares, the days-to-cover ratio is currently 0.1 days.

Artelo Biosciences Price Performance

Shares of NASDAQ ARTL opened at $4.69 on Monday. The company has a market capitalization of $3.28 million, a P/E ratio of -0.25 and a beta of 1.41. The company has a 50 day simple moving average of $7.81 and a 200-day simple moving average of $7.97. Artelo Biosciences has a 1 year low of $4.20 and a 1 year high of $28.60.

Artelo Biosciences (NASDAQ:ARTL) last issued its earnings results on Wednesday, August 13th. The company reported ($5.61) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($5.48). As a group, research analysts expect that Artelo Biosciences will post -2.62 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ARTL shares. Weiss Ratings restated a “sell (d-)” rating on shares of Artelo Biosciences in a research report on Saturday, September 27th. D Boral Capital lowered Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 8th. Wall Street Zen downgraded Artelo Biosciences to a “strong sell” rating in a report on Saturday, August 9th. Finally, D. Boral Capital restated a “hold” rating on shares of Artelo Biosciences in a report on Monday, September 8th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $24.00.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.